Feb 5, 2019
JP Milon is CEO of Paris-based Quantum Genomics, a company developing a treatment for patients with hypertension that is resistant to currently available medications. Over-represented in populations with resistant hypertension, minorities often suffer severe complications as a result of having perpetual high blood pressure. JP discusses firibastat, Quantum Genomic's experimental drug which works by acting on the part of the brain that lowers blood pressure and could potentially help these under-served patients.
#hypertension #cardiology #treatmentresistance #biotech